Diarrhea News and Research

Latest Diarrhea News and Research

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

New case of MERS CoV confirmed in Thailand, other states in WHO South-East Asia Region cautioned to remain vigilant

Thailand today confirmed Middle East respiratory syndrome coronavirus disease in a traveler, the second such case in the country in the last seven months, as WHO cautioned other member states in its South-East Asia Region against the continuing risks and the need to remain vigilant.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Building Health Check launches IAQ Screening Kit for E. coli bacteria

Following a number of recent outbreaks of E. coli, or Escherichia coli, bacteria at grocers and restaurants across the country, Building Health Check, LLC, has released an Indoor Air Quality (IAQ) Screening Kit for the E. coli bacteria.

26 Jan 2016

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection.

21 Jan 2016

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic has added robots in its fight against Clostridium difficile (C-diff) bacteria. In the U.S., C-diff is one of the most common infections patients can get while receiving care at a health care facility. C-diff can cause a variety of symptoms, including potentially deadly diarrhea. A recent national report shows some progress in reducing C-diff infections; however, more work remains.

20 Jan 2016

Frozen fecal transplantation effective at providing relief to C. diff patients

Frozen fecal transplantation is effective at providing relief to Clostridium difficile (C. diff) patients, according to a new study co-authored by University of Guelph researchers.

18 Jan 2016

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor.

18 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

Simple paper test could confirm presence of illnesses even before patients feel symptoms

A multi-disciplinary team of researchers has developed a new diagnostic test that can change the medical landscape by making it possible for patients to quickly determine if they are infected with an illness, using a simple paper test sensitive enough to detect markers of various illnesses using minute amounts of blood, sweat, or other biological material.

13 Jan 2016

Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Antibiotics that fight infection can adversely affect the digestive tract and give destructive bacteria a chance to flourish, said assistant professor of veterinary and biomedical sciences Joy Scaria of South Dakota State University. His research seeks to identify probiotic mixes to treat intestinal infections, such as Clostridium difficile.

12 Jan 2016

Discoveries could lead to development of novel therapies to prevent C. diff infection

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired diarrhea in the United States.

12 Jan 2016

Ebola health-care workers develop guidelines for treating children during future outbreaks

When the Ebola virus outbreak erupted in West Africa in 2014, children infected with the virus -- particularly those under age 5 -- faced overwhelming challenges. Not only was there a high death rate among young children infected with the disease, they often were isolated from their families, leaving them feeling distressed and without the intensive care they needed.

8 Jan 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

4 Jan 2016

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

For some time doctors have known that psychological therapies can reduce the symptoms of irritable bowel syndrome in the short term.

29 Dec 2015

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center.

24 Dec 2015

Diarrhea News and Research

Latest Diarrhea News and Research

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

New case of MERS CoV confirmed in Thailand, other states in WHO South-East Asia Region cautioned to remain vigilant

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Building Health Check launches IAQ Screening Kit for E. coli bacteria

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Mayo Clinic adds robots to prevent C-diff bacteria

Frozen fecal transplantation effective at providing relief to C. diff patients

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Simple paper test could confirm presence of illnesses even before patients feel symptoms

Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Discoveries could lead to development of novel therapies to prevent C. diff infection

Ebola health-care workers develop guidelines for treating children during future outbreaks

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

New oral breast cancer drug has potential to combat other types of cancer

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

Selexipag holds promise for treatment of pulmonary hypertension

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Diarrhea News and Research

Latest Diarrhea News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in